PT-141 for Women vs Men: Dosing and What to Expect

PT-141, also called bremelanotide, is a melanocortin-receptor peptide that has been studied in both female and male research settings. One reason the question of PT-141 for women versus men comes up so often is that the clinical record differs by sex. The compound reached formal approval for one female indication, while most male data sits in earlier-stage research. That split shapes the dose figures, the onset notes, and the side-effect profile people reference.

Everything here is third-person reference information for research and educational use. It is not dosing advice, and PT-141 is not approved for human consumption. Whether or how much anyone uses is a decision for a licensed clinician. This guide compares the published reference points by sex and shows the unit math, but it does not tell you what to do.

Why the female and male records differ

PT-141 was developed and approved as a subcutaneous product for one specific condition in premenopausal women, so the female reference figures come from a defined clinical program. Male use, by contrast, appears mainly in older injectable and intranasal research and in general literature rather than an approved label. So when sources list a single milligram figure, it usually traces back to the female program, and male reference numbers are looser by comparison.

Reference dose figures by sex

The most-cited female reference figure is a single 1.75 mg subcutaneous administration, the amount tied to the approved product. Male research literature is generally discussed in a broader 1 to 2 mg range per administration, without a single approved number. Both sit inside the same overall band, which is why one reconstituted vial covers either set of figures.

• Female reference (approved label): 1.75 mg per administration
• Male research range: commonly 1 to 2 mg per administration
• Shared cap referenced in labeling: at most one dose per 24 hours

These are arithmetic reference points, not recommendations. The companion PT-141 dosage guide walks through the full reconstitution method; the section below shows how each milligram figure lands in syringe units.

Converting the figures to syringe units

Reconstitution turns a powder vial into a measurable liquid. A common reference setup is a 10 mg vial mixed with 2 mL of bacteriostatic water, which gives 5 mg/mL. Draw volume equals dose divided by concentration, and units equal draw volume times 100 on a U-100 insulin syringe. At 5 mg/mL the sex-specific figures convert like this.

• 1 mg = 0.20 mL = 20 units
• 1.75 mg (female reference) = 0.35 mL = 35 units
• 2 mg = 0.40 mL = 40 units

The math is identical regardless of who the figure is for; only the milligram input changes. To run a different vial size or water volume, the reconstitution calculator and the mg to units converter isolate each step so you do not have to redo the whole conversion by hand.

Onset and timing

PT-141 is not instantaneous, and the timing notes are broadly similar across sexes. Clinical labeling describes administration roughly 45 minutes ahead of anticipated activity. Some research literature mentions a window that can extend longer than that. The 45-minute figure is the most commonly cited reference point, and it appears in the female label as well as general male research notes.

• Reference timing: about 45 minutes before anticipated activity
• Spacing referenced in labeling: at most one administration per 24 hours
• Monthly figure in the female label: no more than 8 administrations per month

Side effects: flushing, nausea, and more

The side-effect profile is where the female record is most detailed, because the approval studies tracked these systematically. The items reported most often are flushing, nausea, and headache. Nausea was the most frequently reported in the female trials, and a smaller share of participants discontinued because of it. Injection-site reactions also appear in the reference material.

• Nausea: the most frequently reported effect in the female program
• Flushing: common, linked to the melanocortin mechanism
• Headache: among the more frequently listed effects
• Injection-site reactions: redness or irritation at the site
• Transient blood-pressure changes: noted in labeling, which is why a single 24-hour dose limit is referenced

Male research literature describes overlapping effects, flushing and nausea included, but with less systematic reporting than the female program. A separate, longer-term cosmetic note in the melanocortin class is skin or mole darkening with repeated exposure, since these receptors also influence pigmentation. For general approaches to GLP-class queasiness that some readers ask about alongside peptides, see managing nausea; note that is a different compound class and shared only as background.

Putting the comparison together

The practical takeaway is that the female reference set is more defined (a single 1.75 mg figure, a documented side-effect list, a monthly cap) while male figures are a looser 1 to 2 mg research range. The reconstitution math, the roughly 45-minute timing note, and the flushing and nausea effects are broadly shared. If you change the vial, the water volume, or the milligram figure, recompute from scratch rather than reusing an old unit count. The same tools that handle PT-141 also cover other research peptides.